(Q38033044)

English

Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials.

scientific article published on 10 August 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

0 references

Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Mary Angelyn Bethel

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Benjamin Cairns

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Francesca L Crowe

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

21

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

author name string

R J Stevens

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

R Ali

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

C R Bankhead

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

R P Camisasca

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

A J Farmer

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

S Harrison

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

P Home

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

R Perera

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

A Plüddemann

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

A Ramachandran

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

N W Roberts

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

P W Rose

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

A Schweizer

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

G Viberti

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

publication date

10 August 2012

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

number of pages

11

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

55

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

2593-2603

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

https://scigraph.springernature.com/pub.10.1007/s00125-012-2653-7

0 references

Diabetes mellitus, fasting glucose, and risk of cause-specific death

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Metformin and reduced risk of cancer in diabetic patients

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Methods for Trend Estimation from Summarized Dose-Response Data, with Applications to Meta-Analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Beta blockade during and after myocardial infarction: an overview of the randomized trials

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Comparative outcomes study of metformin intervention versus conventional approach the COSMIC Approach Study

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical t

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Those confounded vitamins: what can we learn from the differences between observational versus randomised trial evidence?

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Cohort study of pioglitazone and cancer incidence in patients with diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Combined randomised controlled trial experience of malignancies in studies using insulin glargine

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Prevention of pancreatic cancer induction in hamsters by metformin

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Metformin, diet and breast cancer: an avenue for chemoprevention.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/22875195

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults

1 reference

https://pubmed.ncbi.nlm.nih.gov/22875195

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Metformin slows down ageing processes at the cellular level in SHR mice].

1 reference

https://pubmed.ncbi.nlm.nih.gov/22875195

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/22875195

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metformin and risk of cardiovascular disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/22875195

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metformin induces apoptosis of lung cancer cells through activating JNK/p38 MAPK pathway and GADD153

1 reference

https://pubmed.ncbi.nlm.nih.gov/22875195

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00125-012-2653-7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38033044&oldid=1766079392"